FGFR2 (10q26.1) Rearrangement, FISH, Tissue
Use
The FGFR2 (10q26.1) Rearrangement test provides prognostic information and guides treatment for patients with cholangiocarcinomas and other tumor types including bladder, thyroid, oral cavity, and brain cancers. FGFR2 gene rearrangement leads to overexpression of FGFR2, enabling targeted therapy using FGFR2 inhibitors. Identifying this genetic rearrangement can therefore aid in determining personalized treatment options for improved clinical outcomes.
Special Instructions
Not provided.
Limitations
FISH assays may not be successful with non-formalin fixed tissues or decalcified paraffin-embedded tissues, as the success rate is approximately 50%. The test isn't approved by the FDA and should be used as an adjunct to existing clinical and pathologic information. If insufficient tissue is present, the test may be canceled. Additional probes used at consultant discretion incur extra charges. If no FISH signals are observed post-hybridization, results indicating a lack of FISH findings will be reported.
New York Approved
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Formalin-fixed, paraffin-embedded tumor tissue block
Collection Instructions
Submit a formalin-fixed, paraffin-embedded tumor tissue block. Blocks prepared with alternative fixation methods may be acceptable; provide fixation method used.
Storage Instructions
Ambient (preferred) or refrigerated